C4 Therapeutics Reports Exit/Disposal Activities, Reg FD Disclosure

TL;DR

**C4 Therapeutics is making moves that could cut costs or change strategy, watch for details.**

AI Summary

C4 Therapeutics, Inc. filed an 8-K on January 9, 2024, reporting an event that occurred on January 8, 2024, related to 'Cost Associated with Exit or Disposal Activities' and 'Regulation FD Disclosure'. This filing indicates potential restructuring or strategic changes within the company, which could impact future financial performance. Investors should pay attention to the details of these activities as they may signal efforts to streamline operations or reallocate resources, potentially affecting the company's profitability and stock valuation.

Why It Matters

This filing signals potential operational changes at C4 Therapeutics, which could lead to cost savings or strategic shifts, directly impacting the company's financial health and future stock performance.

Risk Assessment

Risk Level: medium — While 'exit or disposal activities' can lead to efficiencies, they also carry execution risks and could signal underlying challenges, making the situation moderately risky.

Analyst Insight

A smart investor would await further details on the 'exit or disposal activities' to understand the scope and financial impact before making any significant investment decisions, as these could be either positive (cost-cutting) or negative (asset sales due to distress).

Key Players & Entities

• C4 Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 9, 2024 (date) — date of the 8-K filing
• January 8, 2024 (date) — date of the earliest event reported
• Delaware (company) — state of incorporation for C4 Therapeutics, Inc.
• Nasdaq (company) — exchange where C4 Therapeutics, Inc. Common Stock is registered

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Glo
• $3 million — it will incur charges of approximately $3 million. The Company anticipates recognizing th

Filing Documents

• cccc-20240109.htm (8-K) — 33KB
• pressreleaseissuedjanuary9.htm (EX-99.1) — 31KB
• c4tlogo1.jpg (GRAPHIC) — 9KB
• 0001628280-24-000947.txt ( ) — 213KB
• cccc-20240109.xsd (EX-101.SCH) — 2KB
• cccc-20240109_lab.xml (EX-101.LAB) — 24KB
• cccc-20240109_pre.xml (EX-101.PRE) — 13KB
• cccc-20240109_htm.xml (XML) — 3KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On January 9, 2024, C4 Therapeutics, Inc. (the "Company") announced that, following a strategic review, it was focusing its capital allocation on programs with the highest potential for value creation and patient impact. The Company is making purpose-led changes to align with its mission and vision and ensure the Company is well positioned for the future. These changes are designed to optimize the Company's cost structure by reducing the size of its workforce (the "Restructuring"). The Company is prioritizing investment in the execution of its Phase 1/2 clinical trial of CFT7455, an oral degrader of IKZF1/3 for the potential treatment of relapsed refractory multiple myeloma and relapsed refractory non-Hodgkin's lymphomas and its Phase 1/2 clinical trial of CFT1946, an oral degrader targeting BRAF V600X mutations for the potential treatment of solid tumors including non-small cell lung cancer, colorectal cancer and melanoma; supporting collaboration partners in drug discovery efforts; and advancing the Company's proprietary internal programs. The employees impacted by the strategic imperatives and resulting Restructuring were notified on January 9, 2024 and represent approximately 30% of the workforce or 45 positions. The reductions will be substantially complete by the end of the first quarter of 2024. As a result of these changes, the Company estimates that it will incur charges of approximately $3 million. The Company anticipates recognizing the majority of these expenses in the first quarter of 2024. The estimates of costs, expenses and savings that the Company expects to incur in connection with the changes are contingent upon various assumptions and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events related to or resulting from these strategic steps.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 9, 2024, the Company issued a press release announcing the Restructuring, its key milestones for 2024, and preliminary financial information, including its unaudited cash, cash equivalents, and marketable securities as of January 5, 2024. The full text of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the Company's expectations regarding the timing and results of the Restructuring; the estimated charges and costs expected to be incurred therewith; the Company's ability to successfully implement its cost-saving initiatives and to capture expected efficiencies; and expectation that the Restructuring will preserve its cash runway into 2027. The use of words such as "anticipate," "believe," "continue," "could," "endeavor," "estimate," "expect," "anticipate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "will" or "would" or the negative of such words or other similar expressions can be used to identify forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. These and other risks and uncertainties are described in additional detail in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K filed February 23, 2023, its Quarterly Reports on Form 10-Q filed on May 4, 2023, August 8, 2023, and November 10, 2023, and its other filings made with the Securities and Exchange Commission from time to time. Although the Company's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this Current Report on Form 8-K speaks only as of the date on which it is made. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new informat

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. Exhibit Number Description 99.1 Press release issue d January 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. C4 Therapeutics, Inc. Date: January 9, 2024 By: /s/ Kendra R. Adams Kendra R. Adams Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR